Identification of a new series of amides as non-covalent proteasome inhibitors

European Journal of Medicinal Chemistry

Volumn 76, Issue , 2014, Pages 1-9

  Scarbaci, Kety ^a   Troiano, Valeria ^a   Micale, Nicola ^a   Ettari, Roberta ^b   Tamborini, Lucia ^b   Di Giovanni, Carmen ^c   Cerchia, Carmen ^c   Grasso, Silvana ^a   Novellino, Ettore ^c   Schirmeister, Tanja ^d   Lavecchia, Antonio ^c   Zappalà, Maria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Amides; Docking studies; Non covalent inhibitors; Proteasome inhibitors

Indexed keywords

2 (4 DIETHYLAMINO 2 OXO 2H PYRIDIN 1 YL)N ISOPENTYL ACETAMIDE; 2 (4 MORPHOLIN 4 YL 2 OXO 2H PYRIDIN 1 YL)N ISOPENTYL ACETAMIDE; 2 [2 OXO 4 PHENYLAMINO PYRIDIN 1 (2H)YL]N PHENYL ACETAMIDE; 2 [2 OXOPYRIDIN 1(2H)YL]N PHENYLACETAMIDE; 2 [8 BROMO 5 OXO 1,6 NAPHTHYRIDIN 6(5H)YL] N ISOPENTYLACETAMIDE; AMIDE; BORTEZOMIB; CHYMOTRYPSIN; N (2 BENZOYLPHENYL) 2 (2 OXO 2H PYRIDIN 1 YL)ACETAMIDE; N (2 BENZOYLPHENYL) 2 (2 OXO 4 PHENYLAMINO 2H PYRIDIN 1 YL)ACETAMIDE; N (4 METHOXYPHENYL) 2 [2 OXO 4 PHENYLAMINO PYRIDIN 1 (2H)YL]ACETAMIDE; N (4 METHOXYPHENYL) 2 [2 OXOPYRIDIN 1(2H)YL]ACETAMIDE; N ADAMANT 1 YL 2 (2 OXO 2H PYRIDIN 1 YL)ACETAMIDE; N ADAMANT 1 YL 2 (2 OXO 4 PHENYLAMINO 2H PYRIDIN 1 YL)ACETAMIDE; N BENZYL 2 [2 OXO 4 PHENYLAMINO PYRIDIN 1(2H)YL]ACETAMIDE; N BENZYL 2 [2 OXOPYRIDIN 1(2H)YL]ACETAMIDE; N ISOPENTYL 2 (2 OXO 3,4,5,6 TETRAHYDRO 2H,2H [1,4 BIPYRIDINYL 1 YL)ACETAMIDE; N ISOPENTYL 2 (2 OXO 4 PHENYLAMINO 2H PYRIDIN 1 YL)ACETAMIDE; N ISOPENTYL 2 (5 OXO 1,6NAPHTHYRIDIN 6 (5H)YL)PROPANAMIDE; N ISOPENTYL 2 [1,2,3,4 TETRAHYDRO 1 METHYL 5 OXO 1,6 NAPHTHYRIDIN 6 (5H)YL]ACETAMIDE; N ISOPENTYL 2 [1,2,3,4 TETRAHYDRO 5 OXO 1,6 NAPHTHYRIDIN 6 (5H)YL]ACETAMIDE; N ISOPENTYL 2 [5 OXO 1,6 NAPHTHYRIDIN 6(5H)YL]ACETAMIDE; PROTEASOME; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; COVALENT BOND; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; MOLECULAR DOCKING; NONHUMAN; PROTEIN DEGRADATION; YEAST; CHEMISTRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

AMIDES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DOCKING SIMULATION; PROTEASOME INHIBITORS;

EID: 84896718936     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.01.022     Document Type: Article

References (49)

1. M. Unno, T. Mizushima, Y. Morimoto, Y. Tomisugi, K. Tanaka, N. Yasuoka, and T. Tsukihara The structure of the mammalian 20S proteasome at 2.75 Å resolution Structure 10 2002 609 618 (Pubitemid 34518706)
2. M. Groll, L. Ditzel, J. Lowe, M. Bochtler, H.D. Bartunik, and R. Huber Structure of 20S proteasome from yeast at 2.4 Å resolution Nature 386 1997 463 471 (Pubitemid 27164066)
3. P.M. Kloetzel Antigen processing by the proteasome Nat. Rev. Mol. Cell Biol. 2 2001 179 187
4. A. Sacco, M. Aujay, B. Morgan, A.K. Azab, P. Mais, Y. Liu, Y. Zhang, F. Azab, H.T. Ngo, G.C. Issa, P. Quang, A.M. Roccaro, and I.M. Ghobria Chymotrypsin-like activity of the proteasome leads to antitumor carfilzomib-dependent selective inhibition of the activity in Waldenstrom's macroglobulinemia Clin. Cancer Res. 17 2011 1753 1764
5. S. Meiners, A. Ludwig, V. Stangl, and K. Stangl Proteasome inhibitors: poisons and remedies Med. Res. Rev. 28 2008 309 327 (Pubitemid 351281191)
6. E.M. Huber, and M. Groll Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development Angew. Chem. Int. Ed. 51 2012 8708 8720
7. J. Wang, and M.A. Maldonado The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases Cell. Mol. Immunol. 3 2006 255 261
8. B. Skaug, X. Jiang, and Z.J. Chen The role of ubiquitin in NFkappaB regulatory pathways Annu. Rev. Biochem. 78 2009 769 796
9. G. Bonuccelli, F. Sotgia, F. Capozza, E. Gazzerro, C. Minetti, and M.P. Lisanti Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice Cell Cycle 6 2007 1242 1248 (Pubitemid 47327991)
10. B.A. Azakir, S. Di Fulvio, J. Kinter, and M. Sinnreich Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells J. Biol. Chem. 287 2012 10344 10354
11. R.T. Jagoe, and A.L. Goldberg What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr. Opin. Clin. Nutr. Metab. Care 4 2001 183 190 (Pubitemid 33682075)
12. C. Lindenthal, N. Weich, Y.S. Chia, V. Heussler, and M.Q. Klinkert The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites Parasitology 131 Part 1 2005 37 44 (Pubitemid 41008807)
13. H. Li, E.L. Ponder, M. Verdoes, K.H. Asbjornsdottir, E. Deu, L.E. Edgington, J.T. Lee, C.J. Kirk, S.D. Demo, K.C. Williamson, and M. Bogyo Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity Chem. Biol. 19 2012 1535 1545
14. Z. Li, C.B. Zou, Y. Yao, M.A. Hoyt, S. McDonough, Z.B. Mackey, P. Coffino, and C.C. Wang An easily dissociated 26S proteasome catalyzes an essential ubiquitin-mediated protein degradation pathway in Trypanosoma brucei J. Biol. Chem. 277 2002 15486 15498 (Pubitemid 34967815)
15. D. Steverding The proteasome as a potential target for chemotherapy of African trypanosomiasis Drug Dev. Res. 68 2007 205 212 (Pubitemid 350223931)
16. D. Steverding, X. Wang, B.C. Potts, and M.A. Palladino Trypanocidal activity of beta-lactone-gamma-lactam proteasome inhibitors Planta Med. 78 2012 131 134
17. G. Lin, D. Li, L.P. de Carvalho, H. Deng, H. Tao, G. Vogt, K. Wu, J. Schneider, T. Chidawanyika, J.D. Warren, H. Li, and C. Nathan Inhibitors selective for mycobacterial versus human proteasomes Nature 461 2009 621 626
18. P. Beck, C. Dubiella, and M. Groll Covalent and non-covalent reversible proteasome inhibition Biol. Chem. 393 2012 1101 1120
19. S. Arastu-Kapur, J.L. Anderl, M. Kraus, F. Parlati, K.D. Shenk, S.J. Lee, T. Muchamuel, M.K. Bennett, C. Driessen, and A.J. Ball et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events Clin. Cancer Res. 17 2011 2734 2743
20. R. Ettari, L. Tamborini, I.C. Angelo, N. Micale, A. Pinto, C. De Micheli, and P. Conti Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis J. Med. Chem. 56 2013 5637 5658
21. R. Ettari, M. Zappalà, N. Micale, G. Grazioso, S. Giofrè, T. Schirmeister, and S. Grasso Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors Eur. J. Med. Chem. 46 2011 2058 2065
22. F. Bova, R. Ettari, N. Micale, C. Carnovale, T. Schirmeister, C. Gelhaus, M. Leippe, S. Grasso, and M. Zappalà Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors Bioorg. Med. Chem. 18 2010 4928 4938
23. N. Micale, R. Ettari, T. Schirmeister, A. Evers, C. Gelhaus, M. Leippe, M. Zappalà, and S. Grasso Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors Bioorg. Med. Chem. 17 2009 6505 6511
24. R. Ettari, M. Zappalà, N. Micale, T. Schirmeister, C. Gelhaus, M. Leippe, A. Evers, and S. Grasso Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain Eur. J. Med. Chem. 45 2010 3228 3233
25. M. Groll, N. Gallastegui, X. Maréchal, V. Le Ravalec, N. Basse, N. Richy, E. Genin, R. Huber, L. Moroder, J. Vidal, and M. Reboud-Ravaux 20S proteasome inhibition: designing noncovalent linear peptide mimics of the natural product TMC-95A ChemMedChem 5 2010 1701 1705
26. E. Genin, M. Reboud-Ravaux, and J. Vidal Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry Curr. Top. Med. Chem. 10 2010 232 256
27. J. Kaffy, G. Bernadat, and S. Ongeri Non-covalent proteasome inhibitors Curr. Pharm. Des. 19 2013 4115 4130
28. R. Ettari, C. Bonaccorso, N. Micale, C. Heindl, T. Schirmeister, M.L. Calabrò, S. Grasso, and M. Zappalà Development of novel peptidomimetics containing a vinyl sulfone moiety as proteasome inhibitors ChemMedChem 6 2011 1228 1237
29. N. Micale, R. Ettari, A. Lavecchia, C. Di Giovanni, K. Scarbaci, V. Troiano, S. Grasso, E. Novellino, T. Schirmeister, and M. Zappalà Development of peptidomimetic boronates as proteasome inhibitors Eur. J. Med. Chem. 64 2013 23 34
30. R.T. Lum, M.G. Nelson, A. Joly, A.G. Horsma, G. Lee, S.M. Meyer, M.M. Wick, and S.R. Schow Selective inhibition of the chymotrypsin-like activity of the 20S proteasome by 5-methoxy-1-indanone dipeptide benzamides Bioorg. Med. Chem. Lett. 8 1998 209 214 (Pubitemid 28066335)
31. C. Garcìa-Echeverrìa, P. Imbach, D. France, P. Fürst, M. Lang, M. Noorani, D. Scholz, J. Zimmermann, and P. Furet A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome Bioorg. Med. Chem. Lett. 11 2001 1317 1319 (Pubitemid 32434360)
32. H.R. Snyder, J.A. Kuck, and J.R. Johnson Organoboron compounds, and the study of reaction mechanisms. Primary aliphatic boronic acids J. Am. Chem. Soc. 60 1938 105 111
33. J.R. Johnson, M.G. Van Campen Jr., and O. Grummit Organoboron compounds. II. The reducing action of some organoboronic acids J. Am. Chem. Soc. 60 1938 111 115
34. M. Groll, C.R. Berkers, H.L. Ploegh, and H. Ovaa Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome Structure 14 2006 451 456 (Pubitemid 43363478)
35. M. Groll, R. Huber, and B.C. Potts Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactam ring opening and a mechanism for irreversible binding J. Am. Chem. Soc. 128 2006 5136 5141
36. E.J. Corey, and W.D. Li Total synthesis and biological activity of lactacystin, omuralide and analogs Chem. Pharm. Bull. 47 1999 1 10 (Pubitemid 29078725)
37. M. Nett, T.A. Gulder, A.J. Kale, C.C. Hughes, and B.S. Moore Function-oriented biosynthesis of beta-lactone proteasome inhibitors in Salinispora tropica J. Med. Chem. 52 2009 6163 6167
38. Maestro, Version 9.2 2011 Schrödinger, LLC New York, NY
39. C.C. Huang, G.S. Couch, E.F. Pettersen, and T.E. Ferrin Chimera: an extensible molecular modelling application constructed using standard components Pac. Symp. Biocomput. 1 1996 724 http://www.cgl.ucsf.edu/chimera
40. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748 (Pubitemid 27170693)
41. GOLD, Version 5.2 2012 The Cambridge Crystallographic Data Centre Cambridge, U.K.
42. W.L. DeLano, The PyMOL Molecular Graphics System, DeLano Scientific LLC, San Carlos, CA, USA, http://www.pymol.org/.
43. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins Struct. Funct. Genet. 52 2003 609 623 (Pubitemid 37034158)
44. G. Fracchiolla, A. Laghezza, L. Piemontese, P. Tortorella, F. Mazza, R. Montanari, G. Pochetti, A. Lavecchia, E. Novellino, S. Pierno, D. Conte Camerino, and F. Loiodice New 2-aryloxy-3-phenyl-propanoic acids as PPAR α/γ dual agonists with improved potency and reduced adverse effects on skeletal muscle function J. Med. Chem. 52 2009 6382 6393
45. C. La Motta, S. Sartini, L. Mugnaini, S. Salerno, F. Simorini, S. Taliani, A.M. Marini, F. Da Settimo, A. Lavecchia, E. Novellino, L. Antonioli, M. Fornai, C. Blandizzi, and M. Del Tacca Exploiting the pyrazolo[3,4-d] pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors J. Med. Chem. 52 2009 1681 1692
46. L. Porcelli, F. Gilardi, A. Laghezza, L. Piemontese, N. Mitro, A. Azzariti, F. Altieri, L. Cervoni, G. Fracchiolla, M. Giudici, U. Guerrini, A. Lavecchia, R. Montanari, C. Di Giovanni, A. Paradiso, G. Pochetti, G.M. Simone, P. Tortorella, M. Crestani, and F. Loiodice Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity J. Med. Chem. 55 2012 37 54
47. M.G. Perrone, P. Vitale, P. Malerba, A. Altomare, A. Lavecchia, C. Di Giovanni, E. Novellino, and A. Scilimati Core ring nature in diarylheterocycle COX-1 inhibitors ChemMedChem 7 2012 629 641
48. R. Vicik, M. Busemann, C. Gelhaus, N. Stiefl, J. Scheiber, W. Schmitz, F. Schulz, M. Mladenovic, B. Engels, M. Leippe, K. Baumann, and T. Schirmeister Aziridide-based inhibitors of cathepsin L: synthesis, inhibition activity, and docking studies ChemMedChem 1 2006 1126 1141 (Pubitemid 44622252)
49. R. Ettari, E. Nizi, M.E. Di Francesco, M.A. Dude, G. Pradel, R. Vicik, T. Schirmeister, N. Micale, S. Grasso, and M. Zappalà Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors J. Med. Chem. 51 2008 988 996 (Pubitemid 351304707)